Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sir Mortimer B. Davis - Jewish General Hospital
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male
Age 18 years or older
Documented metastatic adenocarcinoma of the prostate
Under active medical oncology care
ECOG performance status 0 - 3, inclusive
Able to understand and provide written informed consent
Able to tolerate the physical requirements of two PET/CT scans including lying for up to 30 minutes
Progressive disease on any of: bone scan, CT, MRI or serum PSA as judged by the investigator
Serum prostate specific antigen ≥ 1 ng/ml at baseline or CT/MRI soft-tissue measurable disease as per RECIST v1.1
You may not be if
Life expectancy of at least 3 months as judged by the investigator
Medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)
Exceeding the weight limit of the PET/CT bed (approximately 400 lbs.) or who cannot fit through the PET/CT bore (approximately 70 cm diameter)
Unmanageable claustrophobia
Prior failure of PSMA RLT
Prior hemi-body irradiation
Impaired organ function as evidenced by any of the following laboratory values:
* Absolute neutrophil count \< 1.5 x109/L
* Platelet count \< 75 x109/L
* Hemoglobin \< 85 g/L
* Albumin \< 2.5 g/dL (25 g/L)
* Total bilirubin \> 2 x ULN (unless in instances of Gilbert's disease)
* AST or ALT \> 2.5 x ULN (or \> 5.0 x ULN in the presence of liver metastases)
Clareo Health | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
